 Compound 3BC was found to be a promising lead for the development of a multifunctional agent with the ability to inhibit oxidative catabolism of monoamine neurotransmitters, reduce acetylcholinesterase activity, and suppress neuroinflammation. This compound has been shown to have sub-micromolar selectivity for MAOB, low-micromolar activity against acetylcholinesterase, and the ability to inhibit microglial PGE2 production. Furthermore, it has been demonstrated to have comparable activity to donor piezole in a passive avoidance test, suggesting its potential use in treating neurodegenerative diseases. This article was authored by Ahmed H. E. Hassan, Haian Jong Kim, Quiantae Park, and others.